Recent Updates
Recently added Catalysts
BCDA Positive Sentiment Score: 75/100

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

Key Takeaway: BioCardia, Inc. announced that CEO Peter Altman will participate in a fireside chat during the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The discussion will focus on recent developments in the company's therapeutic pipeline, particularly its CardiAMP autologous cell therapy aimed at treating ischemic heart failure. This engagement aims to provide insights into BioCardia's advancements and strategy in cellular therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioCardia is actively engaging with investors through a fireside chat.
  • The focus on their lead CardiAMP therapy highlights innovation in treating ischemic heart failure.
  • Participation in the showcase can enhance visibility and credibility for BioCardia.

Full Press Release Details

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.

Tags

Frequently Asked Questions

Who is BioCardia's CEO?

BioCardia’s CEO is Peter Altman, Ph.D.

What event will Peter Altman participate in?

He will join a fireside chat at the Alliance Global Partners Virtual Healthcare Showcase.

What is the focus of BioCardia's therapeutic development?

The focus is on the CardiAMP autologous cell therapy for ischemic heart failure.

When is the fireside chat scheduled?

The fireside chat is on May 21, 2025, at 03:40 p.m. EDT.

Where is BioCardia, Inc. headquartered?

BioCardia, Inc. is headquartered in Sunnyvale, California.

Last updated: May 21, 2025